Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03783442
Title A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ROU | POL | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS


No variant requirements are available.